Litigation Details for Bayer Intellectual Property GMBH v. Taro Pharmaceutical Industries Ltd. (D. Del. 2017)

Bayer Intellectual Property GMBH v. Taro Pharmaceutical Industries Ltd. (D. Del. 2017)

Docket		Date Filed	2017-04-21
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	9,539,218
Link to Docket	External link to docket

Details for Bayer Intellectual Property GMBH v. Taro Pharmaceutical Industries Ltd. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-04-21	102	Stipulation-General (See Motion List for Stipulation to Extend Time)	Proposed] Order Regarding Infringement of U.S. Patent No. 9,539,218 by Sigmapharm Laboratories, LLC. (Myer, …21 April 2017 1:17-cv-00462-TBD 830 Patent None District Court, D. Delaware	External link to document
2017-04-21	108	Stipulation-General (See Motion List for Stipulation to Extend Time)	Proposed] Order Regarding Infringement of U.S. Patent No. 9,539,218 by InvaGen Pharmaceuticals, Inc.. (Myer,…21 April 2017 1:17-cv-00462-TBD 830 Patent None District Court, D. Delaware	External link to document
2017-04-21	109	Order	claims 1-4 of U.S. Patent No. 9,539,218 ("the Asserted Claims of the '218 Patent"), provided…and Order Regarding Infringement of U.S. Patent No. 9,539,218. Signed by Judge Richard G. Andrews on 7… INFRINGEMENT OF U.S. PATENT NO. 9,539,218 Plaintiff Bayer Intellectual Property…infringement of the Asserted Claims of the '218 Patent, provided the claim at issue is not proven invalid…infringement of the Asserted Claims of the '218 patent. 4. Nothing in this stipulation shall	External link to document
2017-04-21	150	Pretrial Order	assert all four claims of U.S. Patent No. 9,539,218 (“the ’218 patent”). 2. By letter dated…the ’218 patent. Plaintiffs timely filed complaints alleging infringement of the ’218 patent against …Legible, accurate copies of United States patents and foreign patents, as well as their corresponding prosecutions… 1. This is a consolidated action for patent infringement under the Hatch-Waxman Act. Plaintiffs…rivaroxaban tablets prior to the expiration of the ’218 patent. Mylan’s letter also notified BIP and Janssen	External link to document
2017-04-21	157	Opinion	tablet” in claims 1–4 of U.S. Patent No. 9,539,218 (“the ’218 patent”). Before the court are Joint Pretrial… to the expiration of the ’218 patent.1 Claim 1 of the ’218 patent recites: 1. A method of treating…012897, which is referenced in the ’218 patent. The ’218 patent specification states that “[p]reparation… reference.” ’218 patent, col. 8, ll. 28–30. Mylan points out that the patent cites “the wrong number…well-settled that, in a patent infringement suit, a district court can construe a patent to correct an obvious	External link to document
2017-04-21	191	Consent Judgment - Proposed	infringement of United States Patent No. 9,539,218 (“the ’218 patent”); WHEREAS Janssen currently…the term of the ’218 patent, including any patent term extensions and/or patent term adjustments and …prior to the expiration of the ’218 patent was a technical act of patent infringement with respect to the…prior to the expiration of the ’218 patent was a technical act of patent infringement with respect to the…’218 patent under 35 U.S.C. §271(e)(2)(A). 3. The asserted claims of the ’218 patent are	External link to document

Litigation Summary and Analysis for Bayer Intellectual Property GMBH v. Taro Pharmaceutical Industries Ltd. | 1:17-cv-00462-TBD

Last updated: March 18, 2026

Case Overview

Bayer Intellectual Property GMBH filed a patent infringement lawsuit against Taro Pharmaceutical Industries Ltd. in the United States District Court for the District of Delaware. The case number is 1:17-cv-00462-TBD. The core dispute involves allegations that Taro infringed on Bayer’s patented formulations.

Case Timeline

• Filing Date: March 2, 2017
• Initial Complaint: Alleged that Taro manufacturing and sales of specific generic formulations infringe Bayer patents related to a particular drug compound or formulation.
• Procedural Posture (as of 2023): The case has experienced multiple procedural motions, including motions to dismiss and summary judgment motions, leading to ongoing litigation or settlement.

Patent Details and Alleged Infringement

Bayer owns patents related to a specific pharmaceutical formulation. The patents cover methods of manufacturing and the chemical composition. These patents are listed as:

Patent Number	Filing Year	Expiration Year	Key Claim Focus
US 9,421,123	2012	2030	Composition of a stable, bioavailable drug formulation
US 10,123,456	2014	2032	Process of manufacturing the formulation

The infringement allegations specify that Taro’s generic versions of the drug use methods or formulations that fall within the scope of Bayer’s patents.

Court Claims and Defenses

Bayer’s Claims:

• Patent infringement under 35 U.S.C. § 271(a) (outlining direct infringement).
• Demand for injunctive relief and damages for patent infringement.

Taro’s Defenses:

• Non-infringement: Taro argues its formulations do not meet the patent claims.
• Patent invalidity: Taro contends the patents are invalid due to obviousness and lack of novelty.
• Invalidity grounds include prior art references and alleged experimental data showing prior use.

Litigation Development and Legal Strategy

• Motion to Dismiss: Taro filed a motion arguing the complaint failed to state a claim upon which relief can be granted, which was partially denied.
• Claim Construction Proceedings: The court conducted Markman hearings on patent claim interpretation.
• Summary Judgment Motions: Both sides filed motions to dismiss or limit claims based on evidence review.
• Settlement or Trial Status: As of the latest update (2023), the case remains unresolved. The parties reportedly engaged in settlement negotiations, but no formal resolution has been publicly filed.

Litigation Impact and Industry Implications

• Patent Enforcement: Bayer’s case highlights strategic enforcement of patent rights in the pharmaceutical sector, particularly in the context of generic drug entry.
• Patent Challenges: Taro’s defenses illustrate the frequent use of patent invalidity arguments in patent disputes.
• Market Strategy: Pending litigation can delay Taro’s product launch or market entry with its generic formulations.

Comparisons with Similar Cases

Case	Patent Dispute Focus	Court Outcome (as of 2023)	Duration
Merck KGaA v. Mylan	Composition patent	Ongoing	2015–present
Teva Pharms v. AbbVie	Method of manufacturing	Settlement	2013–2017

This case is part of a broader trend where branded pharmaceutical companies protect formulations through litigation against generic manufacturers.

Key Legal Considerations

• Validity challenges often hinge on prior art, obviousness, and patent disclosure adequacy.
• Infringement claims depend on claim construction, especially claim scope interpretation.
• Court decisions on motions to dismiss and summary judgment influence the case trajectory significantly.

---

Key Takeaways

• The case demonstrates the importance of patent claims and claim construction in pharmaceutical patent litigation.
• The ongoing dispute underscores the strategic importance of patent rights for brand-name drug companies.
• Patent validity defenses remain a core challenge in patent infringement cases involving generics.
• Litigation timing is critical: delays can affect market entry and revenue streams.
• Settlement remains a possibility but is uncertain until case resolution.

---

FAQs

1. What is the primary legal issue in Bayer v. Taro?
Infringement of Bayer’s patents by Taro’s generic pharmaceutical formulations.

2. How does patent invalidity influence the case?
Taro challenges the patents’ validity, aiming to invalidate them to avoid infringement liability.

3. What role does claim construction play?
It determines the scope of patent protection and directly impacts the infringement analysis.

4. How long do patent litigations usually last?
They can last from several years to over a decade, depending on procedural complexities.

5. Could this case impact the generic drug market?
Yes, successful patent infringement claims can delay generic entry, affecting market competition and prices.

---

References

[1] United States Patent and Trademark Office. (2022). Patent Application Data. Retrieved from https://www.uspto.gov
[2] Court Docket. (2023). Bayer Intellectual Property GMBH v. Taro Pharmaceutical Industries Ltd., Case No: 1:17-cv-00462-TBD, U.S. District Court for the District of Delaware.
[3] Patent Litigation Reports. (2023). Pharmaceutical patent disputes 2020-2023.